friendreich s ataxia

It may just be symbolic, but the two-year-old gene therapy Capsida Biotherapeutics built its manufacturing site in the shadow of pharma giant Amgen's headquarters, a wink to its greater ambitions.

Read more Show less

Thousand Oaks-based startup Capsida Biotherapeutics launched in April with the goal of treating devastating diseases using gene therapy. The company just announced a big break that could accelerate its plans.

This week the company inked a deal with biopharma giant CRISPR Therapeutics, a leader in gene-based medicine, to co-develop treatments for two rare diseases with no known cure: Lou Gehrig's disease, or amyotrophic lateral sclerosis (ALS), and Friedreich's ataxia.

Read more Show less

Trending